Non-myeloablative stem cell transplantation for the treatment of cancer and life-threatening non-malignant disorders; past accomplishments and future goals

References 

1. Sullivan KM, Weiden PL, Storb R, et al.  Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood. 1989;73:1720–1726
   • MEDLINE
2. Horowitz M, Gale RP, Sondel PM, et al.  Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75:555–562
   • MEDLINE
3. Advisory Committee of the International BMT Registry Ringden O, Horowitz MM. Graft-versus-leukemia reactions in humans. Transplant. Proc. 1989;21:2989–2992
   • MEDLINE
4. Slavin S, Strober S, Fuks Z, Kaplan HS. Long-term survival of skin allografts in mice treated with fractionated total lymphoid irradiation. Science. 1976;193:1252
   • MEDLINE
5. Slavin S. Total lymphoid irradiation. Immunol. Today. 1987;3:88
   • CrossRef
6. Slavin S, Fuks Z, Kaplan HS, Strober S. Transplantation of allogeneic bone marrow without graft vs host disease using total lymphoid irradiation. J. Exp. Med. 1978;147:963–972
   • MEDLINE
   • CrossRef
7. Slavin S, Or R, Naparstek E, Ackerstein A, Weiss L. Cellular-mediated immunotherapy of leukemia in conjunction with autologous and allogeneic bone marrow transplantation in experimental animals and man. Blood. 1988;72(Suppl 1):407a
8. Slavin S, Naparstek E, Nagler A, Ackerstein A, Kapelushnik Y, Or R. Allogeneic cell therapy for relapsed leukemia following bone marrow transplantation with donor peripheral blood lymphocytes. Exp. Hematol. 1995;23:1553–1562
   • MEDLINE
9. Slavin S, Naparstek E, Nagler A, Ackerstein A, Samuel S, Kapelushnik J, et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse post allogeneic bone marrow transplantation. Blood. 1996;87:2195–2204
   • MEDLINE
10. Naparstek E, Nagler A, Or R, Slavin S. Allogeneic cell mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic BMT for hematological malignancies. Clinical Transplants. 1996;281–290
11. Kapelushnik J, Or R, Aker M, Cividalli G, Nagler A, Naparstek E, et al. Allogeneic cell therapy of severe beta thalassemia major by displacement of host stem cells in mixed chimera by donor blood lymphocytes. Bone Marrow Transplant. 1996;19:96–98
12. Slavin S, Weiss L, Morecki S, Weigensberg M. Eradication of murine leukemia with histoincompatible marrow grafts in mice conditioned with total lymphoid irradiation (TLI). Cancer Immunol. Immunother. 1981;11:155–158
13. Eibl B, Schwaighofer H, Nachbaur D, Marth C, Gächter A, Knapp R, et al. Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood. 1996;88:1501–1508
    • MEDLINE
14. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non-malignant hematologic diseases. Blood. 1998;91(3):756–763
    • MEDLINE
15. Kapelushnik J, Or R, Slavin S, Nagler A. Fludarabine based protocol for BMT in Fanconi anemia. Bone Marrow Transplant. 1997;29(12):1109–1110
16. McSweeney PA, Wagner JL, Maloney DG, Radich J, Shizuru J, Bensinger WI, et al. Outpatient PBSC allografts using immunosuppression with low-dose TBI before, and cyclosporine (CSP) and mycophenolate mofetil (MMF) after transplant. Blood. 1998;92(Suppl 1):519a
17. Slavin S, Nagler A, Naparstek E, Varadi G, Ben-Yosef R, Panighari S, Samuel S, Ackerstein A, Or R. A new non-myeloablative protocol using fludarabine and low-dose TBI in preparation for allogeneic blood stem cell transplantation for high risk patients with malignant and non-malignant disorders. In: The American Society of Hematology, (ASH) 41st Annual Meeting. December 3–7,1999; New Orleans, Louisiana, USA. Blood 1999;94(10(Suppl 1)):388b
18. Giralt S, Estey E, Albitar M, et al.  Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood. 1997;89:4531–4536
    • MEDLINE
19. Khouri I, Keating M, Przepiorka D, et al.  Engraftment and induction of GVL with fludarabine based non-ablative preparative regimens in patients with chronic lymphocytic leukemia and lymphoma. Blood. 1996;88(Suppl 1):301a
20. Carella AM, Champlin R, Slavin S, McSweeney P, Strob R. Mini-allografts ongoing trials in humans. Bone Marrow Transplant. 2000;25(4):345–350
    • MEDLINE
    • CrossRef
21. Moscovitch M, Slavin S. Anti-tumor effects of allogeneic bone marrow transplantation in (NZB × NZW)F1 hybrids with spontaneous lymphosarcoma. J. Immunol. 1984;132:997–1000
    • MEDLINE
22. Childs R, Chernoff A, Contentin N, Bahceci E, Schrump D, Leitman S, et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. New Engl. J. Med. 2000;14(343(11)):750–758
23. Slavin S. Cancer immunotherapy with alloreactive lymphocytes. New Engl. J. Med. 2000;343(11):802–803
24. Slavin S, Nagler A, Varadi G, Or R. Graft vs autoimmunity following allogeneic non-myeloablative blood stem cell transplantation in a patient with chronic myelogenous leukemia and severe systemic psoriasis and psoriatic polyarthritis. Exp. Hematol. 2000;28(7):853–857
    • Abstract
    • Full Text
    • Full-Text PDF (46 KB)
    • CrossRef